AUTOLUS THERAPEUTICS PLC
AUTLNASDAQTrading Snapshot
- Day Range
- $1.57 – $1.65
- 52-Week Range
- $1.18 – $2.58
- Volume (shares)
- 2,347,001
- Avg Volume (shares)
- —
- Shares Outstanding
- 266.2M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $76M
- Last Q Revenue
- $46M
- P/E Ratio
- —
- P/S Ratio
- 3.5x
- EPS (TTM)
- $-1.05
- Dividend Yield
- —
- Dilution (1yr)
- +0.0%
AUTOLUS THERAPEUTICS PLC
AUTL
StockOtter · stockotter.spaceAbout AUTOLUS THERAPEUTICS PLC
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Autolus Therapeutics: Key Questions For The Near Term
Autolus Therapeutics remains a Buy, supported by robust product revenue growth and advancing autoimmune pipeline catalysts. Q2 2026 saw product revenue rise to $45.7M, with net loss narrowing and cash runway extended int
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T